RxDoctor Payments Data

Christopher Kocher, MD

Clinical Cardiac Electrophysiology · State College, PANPI 1689645590

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 57 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Amgen$201
  • Novartis$164
  • E.r. Squibb & Sons, L.L.C.$90
  • Johnson & Johnson$50
  • Impulse Dynamics (USA) Inc.$43
  • plus $224 from 9 others

What the payments were for

  • Consulting fees$47525%
  • Travel & lodging$18210%
  • Food & beverage$1,21965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,876 in reported general payments places this provider in the 5th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$143,685
Medicare patients
854
Services billed
2,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban223$247,268
XareltoRivaroxaban52$60,595
EntrestoSacubitril/Valsartan46$55,467
JardianceEmpagliflozin31$38,469
FarxigaDapagliflozin Propanediol13$7,282
Repatha SureclickEvolocumab13$6,888
Metoprolol Succinate217$4,547
Flecainide Acetate48$2,853
Ranolazine ErRanolazine11$2,573
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$2,000
Diltiazem 24hr ErDiltiazem Hcl28$1,393
Amiodarone Hcl46$1,033
Atorvastatin Calcium63$852
Carvedilol72$834
Tiadylt ErDiltiazem Hcl15$831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$247,268223 claims
Johnson & JohnsonXarelto$50$60,59552 claims
NovartisEntresto$164$55,46746 claims
Boehringer IngelheimJardiance$18$38,46931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →